EU-based medical technology start-up secures €1.7 million in funding for expansion
In a significant move, Danish MedTech startup VentriJect has closed a €1.7 million funding round, aiming to expand its innovative cardiorespiratory fitness monitoring device across Europe and the US [1][2][3].
Established in 2018 as a spinout from Aalborg University, VentriJect's technology, Seisomofit, uses seismocardiography to measure cardiorespiratory fitness (CRF) without the need for exercise, providing a VO2 max estimation in under three minutes [3]. This ground-breaking technology has already garnered attention, with clinical accuracy and reproducibility highlighted in a BBC documentary last year [3].
The funding round, which closed in August 2025, will be utilised to enhance market penetration strategies in Europe and the US. With the growing demand for advanced fitness and health monitoring solutions, VentriJect is poised for significant growth in these regions [1][2][3].
The funding was led primarily by existing investors, including the Export and Investment Fund of Denmark (EIFO), demonstrating confidence in VentriJect's future as a market leader in VO2 Max measurements [1]. Anders Throup-Jensen from EIFO expressed his confidence in VentriJect's potential [1].
Denmark is already well recognised as a factory for innovative tech startups, but there is growing interest in healthtech in particular. The country's biotechnology scene is supported by institutions like the BioInnovation Institute (BII), funded by Novo Nordisk [2]. The HealthCap IX fund, focused on Nordic healthtech, is another example of this growing interest [2].
Medtech companies like VentriJect are proving attractive to those looking to gain healthcare exposure but have a lower risk appetite. With its ability to generate revenue more quickly compared to biotechnology companies, VentriJect is well positioned in the market [1]. The CEO of VentriJect, Mikkel Kristiansen, believes the startup will benefit from the wider boom in the Nordic startup scene, particularly in healthtech [1].
The startup has customers in several European markets and has recently signed distributors in Denmark, the Netherlands, Sweden, Switzerland, and the UK [2]. VentriJect is also exploring US market entry, which would provide access to over 55,000 health clubs and the world's largest healthcare market [1].
With this latest funding, VentriJect is set to scale its innovation and position itself for global adoption, marking an exciting period of growth for the Danish MedTech startup.
[1] VentriJect Closes €1.7 Million Funding Round to Expand Cardiorespiratory Fitness Monitoring Device. (2025). [Link] [2] Denmark's Growing Healthtech Scene: VentriJect's Expansion into Europe and the US. (2025). [Link] [3] BBC Documentary Highlights VentriJect's Seisomofit Technology. (2024). [Link]
- The funding round will help VentriJect, a Danish MedTech startup, invest in technology for expanding their cardiorespiratory fitness monitoring device, Seisomofit, across Europe and the US.
- The growth of VentriJect aligns with the booming interest in healthtech in Denmark, a country already recognized for its innovative tech startups, with support from institutions like the BioInnovation Institute.
- VentriJect's attractiveness to investors stems from its ability to generate revenue more quickly compared to biotechnology companies, making it an advantageous choice for those seeking healthcare exposure but with a lower risk appetite.
- With the expansion across Europe and the US, VentriJect's growth also intersects with thriving investment opportunities in science, technology, and health-and-wellness, while putting them in a strong position for long-term business growth and potential for further investing in medical-conditions, fitness-and-exercise, and finance.
